CN111366671B - 同时检测血清中18种类固醇激素的化学衍生-超高效液相色谱-串联质谱法 - Google Patents
同时检测血清中18种类固醇激素的化学衍生-超高效液相色谱-串联质谱法 Download PDFInfo
- Publication number
- CN111366671B CN111366671B CN202010326307.6A CN202010326307A CN111366671B CN 111366671 B CN111366671 B CN 111366671B CN 202010326307 A CN202010326307 A CN 202010326307A CN 111366671 B CN111366671 B CN 111366671B
- Authority
- CN
- China
- Prior art keywords
- mass spectrometry
- performance liquid
- liquid chromatography
- tandem mass
- high performance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003270 steroid hormone Substances 0.000 title claims abstract description 60
- 239000000126 substance Substances 0.000 title claims abstract description 33
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 title claims abstract description 28
- 210000002966 serum Anatomy 0.000 title claims abstract description 23
- 238000001514 detection method Methods 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 38
- 238000001212 derivatisation Methods 0.000 claims abstract description 31
- TVPSRTVMZGECAT-UHFFFAOYSA-N o-(pyridin-3-ylmethyl)hydroxylamine Chemical compound NOCC1=CC=CN=C1 TVPSRTVMZGECAT-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 12
- 238000001819 mass spectrum Methods 0.000 claims abstract description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 42
- 239000000243 solution Substances 0.000 claims description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 26
- 239000012086 standard solution Substances 0.000 claims description 23
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 14
- 229940088597 hormone Drugs 0.000 claims description 13
- 239000005556 hormone Substances 0.000 claims description 13
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 12
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 12
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 10
- 238000000622 liquid--liquid extraction Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 238000000638 solvent extraction Methods 0.000 claims description 10
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 9
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 claims description 9
- -1 (3-pyridyl) methyl group Chemical group 0.000 claims description 8
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 claims description 8
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 8
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 claims description 8
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 7
- 235000019253 formic acid Nutrition 0.000 claims description 7
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 6
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 6
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 claims description 6
- BFZHCUBIASXHPK-QJSKAATBSA-N 11alpha-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)C[C@H]2O BFZHCUBIASXHPK-QJSKAATBSA-N 0.000 claims description 6
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims description 6
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 claims description 6
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims description 6
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 claims description 6
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 6
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 6
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 claims description 6
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 6
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 claims description 6
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 claims description 6
- 229960002478 aldosterone Drugs 0.000 claims description 6
- 229960003473 androstanolone Drugs 0.000 claims description 6
- 229940061641 androsterone Drugs 0.000 claims description 6
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 claims description 6
- 229960004544 cortisone Drugs 0.000 claims description 6
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 claims description 6
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims description 6
- 229960003399 estrone Drugs 0.000 claims description 6
- 229960000890 hydrocortisone Drugs 0.000 claims description 6
- 229960002847 prasterone Drugs 0.000 claims description 6
- 229960000249 pregnenolone Drugs 0.000 claims description 6
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 claims description 6
- 239000000186 progesterone Substances 0.000 claims description 6
- 229960003387 progesterone Drugs 0.000 claims description 6
- 229960003604 testosterone Drugs 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims description 5
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims description 5
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 3
- 229940098773 bovine serum albumin Drugs 0.000 claims description 3
- 238000000132 electrospray ionisation Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 238000004445 quantitative analysis Methods 0.000 claims description 3
- 238000001195 ultra high performance liquid chromatography Methods 0.000 claims description 3
- LKQDFQLSEHWIRK-UKBVDAKRSA-N 3alpha,17alpha-Dihydroxy-5beta-pregnan-20-one Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)C)(O)[C@@]2(C)CC1 LKQDFQLSEHWIRK-UKBVDAKRSA-N 0.000 claims description 2
- 238000000889 atomisation Methods 0.000 claims description 2
- LKQDFQLSEHWIRK-UHFFFAOYSA-N (3alpha,5alpha,17alphaOH)-3,17-Dihydroxypregnan-20-one Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 LKQDFQLSEHWIRK-UHFFFAOYSA-N 0.000 claims 1
- JERGUCIJOXJXHF-UHFFFAOYSA-N 17alpha-Hydroxypregnenolone Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 JERGUCIJOXJXHF-UHFFFAOYSA-N 0.000 claims 1
- JERGUCIJOXJXHF-TVWVXWENSA-N 17alpha-hydroxypregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JERGUCIJOXJXHF-TVWVXWENSA-N 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 22
- 239000012071 phase Substances 0.000 abstract description 15
- 238000000926 separation method Methods 0.000 abstract description 5
- 239000007791 liquid phase Substances 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000007789 gas Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010001343 Adrenal cortical hypofunctions Diseases 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WCFMIRDWWMUQLL-DCFRXHFNSA-N C[C@](CC1)([C@@H]2[C@H](CC3)[C@H]1[C@@](C)(CCC1)C3C1=O)C=CC2=O Chemical compound C[C@](CC1)([C@@H]2[C@H](CC3)[C@H]1[C@@](C)(CCC1)C3C1=O)C=CC2=O WCFMIRDWWMUQLL-DCFRXHFNSA-N 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- AMEDKBHURXXSQO-UHFFFAOYSA-N azonous acid Chemical compound ONO AMEDKBHURXXSQO-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002552 multiple reaction monitoring Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000002444 silanisation Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N2030/009—Extraction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/045—Standards internal
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
Claims (11)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019103397025 | 2019-04-25 | ||
CN201910339702.5A CN110187043A (zh) | 2019-04-25 | 2019-04-25 | 一种同时检测血清中13种甾体激素的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111366671A CN111366671A (zh) | 2020-07-03 |
CN111366671B true CN111366671B (zh) | 2020-10-30 |
Family
ID=67714875
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910339702.5A Pending CN110187043A (zh) | 2019-04-25 | 2019-04-25 | 一种同时检测血清中13种甾体激素的方法 |
CN202010326307.6A Active CN111366671B (zh) | 2019-04-25 | 2020-04-23 | 同时检测血清中18种类固醇激素的化学衍生-超高效液相色谱-串联质谱法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910339702.5A Pending CN110187043A (zh) | 2019-04-25 | 2019-04-25 | 一种同时检测血清中13种甾体激素的方法 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN110187043A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116519850B (zh) * | 2023-06-29 | 2023-09-19 | 四川大学华西医院 | 一种快速检测血清样本中16种激素浓度的方法 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111856044A (zh) * | 2019-10-30 | 2020-10-30 | 美康生物科技股份有限公司 | 全血型冻干粉免疫抑制剂质量控制物质及其制备方法和应用 |
CN110927264A (zh) * | 2019-11-08 | 2020-03-27 | 河北省医疗器械与药品包装材料检验研究院(河北省医疗器械技术审评中心) | 一种血清中糖皮质激素的检测方法及试剂盒 |
CN110865137A (zh) * | 2019-12-03 | 2020-03-06 | 天津国科医工科技发展有限公司 | 一种血浆中醛固酮检测方法及检测试剂盒 |
CN112964815A (zh) * | 2019-12-13 | 2021-06-15 | 中国科学院大连化学物理研究所 | 生物体液多种类固醇激素的检测方法 |
CN112964809A (zh) * | 2019-12-13 | 2021-06-15 | 中国科学院大连化学物理研究所 | 一种检测生物体液多种类固醇激素试剂盒及其使用方法 |
CN110824091A (zh) * | 2019-12-17 | 2020-02-21 | 杭州度安医学检验实验室有限公司 | 一种类固醇激素检测方法 |
CN111398446B (zh) * | 2020-03-12 | 2022-12-16 | 南京品生医学检验实验室有限公司 | 超高效液相色谱串联质谱技术检测血清中12种类固醇激素的方法 |
CN111398447B (zh) * | 2020-03-12 | 2023-05-05 | 南京品生医疗科技有限公司 | 超高效液相色谱串联质谱技术检测血清中12种类固醇激素的试剂盒 |
CN112198265B (zh) * | 2020-03-16 | 2023-07-14 | 广州金域医学检验中心有限公司 | 用于同时检测血液类样本中多种类固醇激素的预处理方法、检测方法及试剂盒 |
CN111337602A (zh) * | 2020-04-26 | 2020-06-26 | 梧州市食品药品检验所 | 一种高效液相色谱串联质谱法测定神经甾体类激素的方法 |
CN112345675B (zh) * | 2020-12-07 | 2022-08-05 | 葵花药业集团湖北武当有限公司 | 同时检测小儿麻甘颗粒中8种活性成分的hplc法 |
CN114624344A (zh) * | 2020-12-10 | 2022-06-14 | 中国科学院大连化学物理研究所 | 一种类固醇激素联合生物标志物及其应用 |
CN112611827B (zh) * | 2020-12-23 | 2022-12-06 | 中南民族大学 | 测3种雌激素的化学衍生-超高效液相色谱-串联质谱法 |
CN112763602A (zh) * | 2020-12-24 | 2021-05-07 | 诸暨市中医医院 | 一种血清中甾体激素的快速检测方法 |
CN113125597B (zh) * | 2021-04-08 | 2023-04-07 | 广州金域医学检验中心有限公司 | 一种17-羟基孕酮和雄烯二酮的检测方法 |
CN113504328A (zh) * | 2021-07-28 | 2021-10-15 | 苏州市药品检验检测研究中心 | 一种化妆品中糖皮质激素和性激素的高通量检测方法 |
CN114487185B (zh) * | 2022-01-21 | 2024-05-28 | 武汉迈特维尔生物科技有限公司 | 一种胆固醇通路的分离鉴定方法 |
CN114544836A (zh) * | 2022-03-11 | 2022-05-27 | 天津国科医工科技发展有限公司 | 检测痕量雌激素、17-羟孕烯醇酮、醛固酮、硫酸脱氢表雄酮的前处理方法及检测方法 |
CN114839285A (zh) * | 2022-04-24 | 2022-08-02 | 江苏中烟工业有限责任公司 | 一种烟用香精特征化合物分析方法及其应用 |
CN114705787B (zh) * | 2022-04-28 | 2024-08-27 | 天津国科医疗科技发展有限公司 | 基于衍生化的干血斑中12种类固醇激素的检测方法 |
CN115541776B (zh) * | 2022-11-03 | 2024-01-19 | 北京大学第三医院(北京大学第三临床医学院) | 利用高效液相色谱-离子淌度差分质谱检测类固醇激素的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003089921A1 (en) * | 2002-04-15 | 2003-10-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for separation and detection of ketosteroids and other carbonyl-containing compounds |
JP5288230B2 (ja) * | 2007-04-27 | 2013-09-11 | 株式会社あすか製薬メディカル | ステロイドの高感度測定法 |
CN103698414A (zh) * | 2012-09-27 | 2014-04-02 | 中国科学院大连化学物理研究所 | 一种基于化学衍生的尿液中甾体激素的检测方法 |
CN104807921A (zh) * | 2015-05-21 | 2015-07-29 | 上海迪安医学检验所有限公司 | 高效液相色谱串联质谱技术检测血清中10种类固醇激素的方法 |
CN105842379A (zh) * | 2016-06-02 | 2016-08-10 | 云南省农业科学院质量标准与检测技术研究所 | 一种衍生化测定酚类雌激素的方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2384437B1 (en) * | 2008-12-24 | 2018-12-12 | Quest Diagnostics Investments Incorporated | Mass spectrometry assay for pregnenolone and 17-hydroxypregnenolone |
CN103185762B (zh) * | 2011-12-29 | 2015-08-26 | 复旦大学 | 一种分析测定食品中多种内分泌干扰物的方法 |
PT3084432T (pt) * | 2013-12-19 | 2018-05-22 | Univ Gent | Quantificação de glucocorticoides em escamas de peixe, espinhas, raios de barbatana ou otólitos como biomarcadores para stresse crónico |
JP2018515796A (ja) * | 2015-05-27 | 2018-06-14 | クエスト ダイアグノスティックス インヴェストメンツ エルエルシー | マイクロサンプリングデバイスにより抽出された被分析物の質量分析による定量のための方法 |
CN104880529B (zh) * | 2015-06-23 | 2016-08-31 | 山东出入境检验检疫局检验检疫技术中心 | 检测动物源食品中残留药物的方法及液质数据库 |
CN105651924B (zh) * | 2016-03-16 | 2018-03-23 | 杭州汉库医学检验所有限公司 | 血液中激素的检测方法 |
US20170328921A1 (en) * | 2016-05-02 | 2017-11-16 | Sanis Biomedical, LLC | Methods for detecting hormones and other analytes |
CN109415402B (zh) * | 2016-05-05 | 2021-10-19 | 印第安纳大学研究与技术公司 | 用于预测自发性早产的孕酮代谢物的定量分析 |
WO2018136085A1 (en) * | 2017-01-20 | 2018-07-26 | Mprobe Inc. | Methods and compositions for providing an early stage ovarian cancer assessment with metabolites |
CN107064400B (zh) * | 2017-04-20 | 2018-09-21 | 博厚健康科技股份有限公司 | 同时检测血清中五种类固醇激素的方法 |
CN107462653B (zh) * | 2017-07-03 | 2020-04-14 | 广西壮族自治区妇幼保健院 | 干血斑中7种类固醇激素的液相色谱串联质谱检测方法 |
CN108088934A (zh) * | 2017-11-17 | 2018-05-29 | 深圳华大生命科学研究院 | 一种同时检测cah多种相关物质的方法和试剂盒 |
CN108445236B (zh) * | 2018-02-07 | 2021-04-20 | 深圳市新产业生物医学工程股份有限公司 | 甾体类衍生物和其保存液以及其应用 |
CN109001335B (zh) * | 2018-09-13 | 2021-06-25 | 山东师范大学 | 用于测定南极磷虾中17种类固醇激素的方法 |
-
2019
- 2019-04-25 CN CN201910339702.5A patent/CN110187043A/zh active Pending
-
2020
- 2020-04-23 CN CN202010326307.6A patent/CN111366671B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003089921A1 (en) * | 2002-04-15 | 2003-10-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for separation and detection of ketosteroids and other carbonyl-containing compounds |
JP5288230B2 (ja) * | 2007-04-27 | 2013-09-11 | 株式会社あすか製薬メディカル | ステロイドの高感度測定法 |
CN103698414A (zh) * | 2012-09-27 | 2014-04-02 | 中国科学院大连化学物理研究所 | 一种基于化学衍生的尿液中甾体激素的检测方法 |
CN104807921A (zh) * | 2015-05-21 | 2015-07-29 | 上海迪安医学检验所有限公司 | 高效液相色谱串联质谱技术检测血清中10种类固醇激素的方法 |
CN105842379A (zh) * | 2016-06-02 | 2016-08-10 | 云南省农业科学院质量标准与检测技术研究所 | 一种衍生化测定酚类雌激素的方法 |
Non-Patent Citations (4)
Title |
---|
Derivatization of neutral steroids to enhance their detection characteristics in liquid chromatography–mass spectrometry;Tatsuya Higashi 等;《Anal Bioanal Chem》;20031104;第378卷;875-882 * |
HPLC-MS/MS同位素稀释法测定人体血清中类固醇激素的研究;周亚飞等;《检验医学》;20150531;第30卷(第05期);427-432 * |
液相色谱-串联质谱法检测血清中15种甾体激素的动态变化;童鸿斌等;《色谱》;20170430;第35卷(第04期);421-426 * |
衍生化技术用于生物基质中类固醇类激素分析的研究进展;胡秋菊等;《医药导报》;20170531;第36卷(第05期);532-537 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116519850B (zh) * | 2023-06-29 | 2023-09-19 | 四川大学华西医院 | 一种快速检测血清样本中16种激素浓度的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN110187043A (zh) | 2019-08-30 |
CN111366671A (zh) | 2020-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111366671B (zh) | 同时检测血清中18种类固醇激素的化学衍生-超高效液相色谱-串联质谱法 | |
CN104807920B (zh) | 一种试剂盒在利用高效液相色谱串联质谱技术检测血清中10种类固醇激素中的应用 | |
CA2826830C (en) | Methods and systems for determining the presence or amount of testosterone in a sample | |
CA2706953C (en) | Methods for detecting dihydroxyvitamin d metabolites by mass spectrometry | |
CN104807921A (zh) | 高效液相色谱串联质谱技术检测血清中10种类固醇激素的方法 | |
EP1613951A1 (en) | Steroid hormone analysis by mass spectrometry | |
CN111721854A (zh) | 一种同时检测血清中11项类固醇激素的方法 | |
CN110927289A (zh) | 一种类固醇激素检测试剂盒 | |
CN110702831B (zh) | 一种超高效液相色谱-串联质谱检测血清睾酮激素的试剂盒 | |
EP3875959A1 (en) | C peptide detection by mass spectrometry | |
CN114674961A (zh) | 一种非衍生化同步检测血清中17种类固醇激素的试剂盒及其应用 | |
CN113049719A (zh) | 一种检测游离睾酮的方法及试剂盒 | |
CN112611827B (zh) | 测3种雌激素的化学衍生-超高效液相色谱-串联质谱法 | |
CN110208393A (zh) | 一种检测血清中5种雄激素的方法 | |
US11536733B2 (en) | Methods and systems for the detection of 11-oxo androgens by LC-MS/MS | |
WO2012087438A1 (en) | Methods for simultaneous quantification of thyroid hormones and metabolites thereof by mass spectrometry | |
CN115963199A (zh) | 一种人/动物体液中类固醇激素的定量检测方法和应用 | |
Vicente et al. | Measurement of serum testosterone using high-performance liquid chromatography/tandem mass spectrometry | |
CN113009036A (zh) | 一种检测性激素的试剂盒、性激素样品前处理方法及同时检测多种性激素的方法 | |
CN116519850B (zh) | 一种快速检测血清样本中16种激素浓度的方法 | |
CN114280192B (zh) | 维生素d及其代谢产物的检测方法 | |
CN115586281A (zh) | 血清25-羟基维生素d的提取系统、方法及联合lc-msms检测法 | |
CN113189242A (zh) | 一种检测血清中游离雌三醇含量的方法及试剂盒 | |
CN116593628B (zh) | 一种基于lc-ms/ms同时检测血清中多种类固醇激素的方法及试剂盒 | |
CN115389648A (zh) | 一种生物体液中多种甾体激素的检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211101 Address after: 430070 room 521, building C6, biological innovation park, No. 666, Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan, Hubei Province Patentee after: Meisbaike (Wuhan) Medical Technology Co.,Ltd. Address before: 430074 No. 708 National Road, Hongshan District, Hubei, Wuhan Patentee before: SOUTH CENTRAL University FOR NATIONALITIES |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231011 Address after: 430000, No. 702, Building 10, Phase 2.1, Wuhan Optics Valley Precision Medical Industry Base, No. 9 Gaokeyuan 3rd Road, Baoxie Street, Wuhan Donghu New Technology Development Zone, Wuhan, Hubei Province (Wuhan Free Trade Zone) Patentee after: Polo (Wuhan) Medical Biotechnology Co.,Ltd. Address before: 430070 room 521, building C6, biological innovation park, No. 666, Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan, Hubei Province Patentee before: Meisbaike (Wuhan) Medical Technology Co.,Ltd. |